Seizure Management & ASM Dosing Pathway

Type-Specific Selection, Weight-Based Loading & Status Epilepticus Timeline
Protocol Note: This module aligns with the Indian Academy of Neurology (IAN) and international consensus guidelines for acute seizure control, weight-based loading of Anti-Seizure Medications (ASMs), and Status Epilepticus time-stamps.

1. Patient Characteristics & Demographics

2. Seizure Phenotype Selection

⚒ Clinical Context & High-Yield Pearls

The rapid, systematic termination of seizure activity prevents permanent excitotoxic neuronal injury and systemic metabolic collapse. Avoid diagnostic paralysis during an active convulsion.

⚠ Safety Alert: Phenytoin Infusion Guidelines

Phenytoin is formulated in a propylene glycol vehicle requiring an alkaline pH. If infused faster than 50 mg/min in adults, it causes severe myocardial depression, bradyarrhythmias, QT prolongation, and life-threatening hypotension. Always dilute only in 0.9% Normal Saline (never dextrose, which causes immediate precipitation), and use an inline filter. Monitor ECG and blood pressure throughout the loading phase.

Sodium Valproate Teratogenicity Risk

Sodium Valproate has the highest rate of major congenital malformations and neurodevelopmental delays among all ASMs when used in pregnancy. In clinical practice, unless managing refractory status epilepticus or myoclonic syndromes where alternatives have entirely failed, Valproate must be strictly avoided in females of childbearing potential. Prefer Levetiracetam or Lamotrigine as first-line maintenance options.

Anti-Seizure Medication Drug Profiles

Drug Name Mechanism of Action High-Yield Clinical Pearl
Levetiracetam SV2A vesicle protein binding Zero hepatic drug interactions. Renally excreted (adjust in AKI/CKD). Can cause behavioral side effects.
Sodium Valproate GABA enhancement, Na channel blockade Broad-spectrum efficacy. Avoid in hepatic failure or suspected mitochondrial disorders. Watch for thrombocytopenia.
Phenytoin Voltage-gated Na channel blockade Exhibits zero-order kinetics at therapeutic concentrations; tiny dose increments can lead to profound toxicity.
Lamotrigine Voltage-gated Na channel blockade Excellent broad-spectrum agent. Requires slow titration to avoid Stevens-Johnson Syndrome (SJS). Safe in pregnancy.
Lacosamide Slow inactivation of Na channels Highly effective for focal seizures. Can prolong the PR interval; use cautiously in baseline heart block.
Carbamazepine / Oxcarbazepine Voltage-gated Na channel blockade Strong CYP450 auto-induction properties (Carbamazepine). Monitor for dose-dependent hyponatremia.
Ethosuximide T-type Calcium channel blockade Narrow spectrum. The definitive first-line agent exclusively for pure absence seizures.
Clonazepam / Clobazam Positive GABA-A modulator Highly effective adjunctive therapy for myoclonic or focal networks. Clobazam has a lower sedative burden.

Bedside Status Epilepticus Diagnostic Checkpoints

  • Check Glucometer Random Blood Sugar (GRBS) Immediately: Hypoglycemia can mimic or provoke status epilepticus. If GRBS is under 60 mg/dL, give 100 mL of 25% Dextrose stat IV (after 100 mg Thiamine if nutritional status is poor to prevent Wernicke's encephalopathy).
  • Correct Severe Hyponatremia: A serum sodium level under 120 mEq/L is a potent seizure trigger. If active convulsing occurs in this context, administer 100 mL of 3% Hypertonic Saline IV over 10 to 15 minutes.
  • Recognize Non-Convulsive Status Epilepticus (NCSE): If a patient fails to regain consciousness within 20 minutes following the termination of motor convulsions, maintain a very high index of suspicion for NCSE and arrange an emergent EEG.
Abbreviations: ASM (Anti-Seizure Medication) · SE (Status Epilepticus) · GTC (Generalized Tonic-Clonic) · IV (Intravenous) · IM (Intramuscular) · IAN (Indian Academy of Neurology) · ILAE (International League Against Epilepsy) · GRBS (Glucometer Random Blood Sugar) · NCSE (Non-Convulsive Status Epilepticus) · EEG (Electroencephalogram) · NS (Normal Saline) · ECG (Electrocardiogram)
Algorithm References & Evidence Base
  1. Glauser T, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48-61.
  2. Indian Academy of Neurology (IAN) Consensus Guidelines on Epilepsy Management.
  3. Trinka E, et al. A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523.
How to Cite This Tool

AMA Style:
Umakanth S., Umakanth S. Seizure Management & ASM Dosing Pathway. MEDiscuss. Published 2026. Accessed .

Vancouver Style:
Umakanth S, Umakanth S. Seizure Management & ASM Dosing Pathway [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

⚠ Disclaimer: This decision-support system is intended for healthcare professionals. It does not substitute clinical judgment. These algorithms are evidence-based, but medical knowledge evolves continuously. The treating physician retains absolute responsibility for all diagnostic, dosing, and therapeutic decisions. Always verify outputs against current institutional protocols and individual patient contexts.
© 2026 MEDiscuss.org. All rights reserved. This CDSS Module was designed and developed by
Dr. Shashikiran Umakanth using the available evidence base. Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Category Therapeutic Pathways & Algorithms
Specialties Neurology / Intensive Care
Status New Pathway
Related Clinical Tools
Acute Hypercalcaemia ProtocolAcute Hyperkalaemia ProtocolAcute Hypernatraemia Protocol
Back to All Medical Calculators & Pathways